Harmony Biosciences Holdings, Inc. (HRMY)
39.64
+0.07
(+0.18%)
USD |
NASDAQ |
Oct 02, 16:00
39.64
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Enterprise Value : 1.857B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.857B |
| October 01, 2026 | 1.853B |
| September 30, 2026 | 1.835B |
| September 29, 2026 | 1.837B |
| September 28, 2026 | 1.879B |
| September 25, 2026 | 1.951B |
| September 24, 2026 | 1.945B |
| September 23, 2026 | 1.906B |
| September 22, 2026 | 1.967B |
| September 21, 2026 | 2.000B |
| September 18, 2026 | 1.995B |
| September 17, 2026 | 2.037B |
| September 16, 2026 | 2.006B |
| September 15, 2026 | 2.004B |
| September 14, 2026 | 1.968B |
| September 11, 2026 | 1.966B |
| September 10, 2026 | 1.942B |
| September 09, 2026 | 1.972B |
| September 08, 2026 | 1.998B |
| September 04, 2026 | 2.009B |
| September 03, 2026 | 1.986B |
| September 02, 2026 | 2.044B |
| September 01, 2026 | 1.951B |
| August 31, 2026 | 1.842B |
| August 28, 2026 | 1.832B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.870B |
| August 26, 2026 | 1.858B |
| August 25, 2026 | 1.817B |
| August 24, 2026 | 1.791B |
| August 21, 2026 | 1.770B |
| August 20, 2026 | 1.766B |
| August 19, 2026 | 1.874B |
| August 18, 2026 | 1.810B |
| August 17, 2026 | 1.770B |
| August 14, 2026 | 1.769B |
| August 13, 2026 | 1.791B |
| August 12, 2026 | 1.865B |
| August 11, 2026 | 1.850B |
| August 10, 2026 | 1.820B |
| August 07, 2026 | 1.786B |
| August 06, 2026 | 1.805B |
| August 05, 2026 | 1.776B |
| August 04, 2026 | 1.807B |
| August 03, 2026 | 1.622B |
| July 31, 2026 | 1.601B |
| July 30, 2026 | 1.637B |
| July 29, 2026 | 1.637B |
| July 28, 2026 | 1.632B |
| July 27, 2026 | 1.646B |
| July 24, 2026 | 1.606B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 2.451B |
| Pfizer Inc. | 210.23B |
| Bristol Myers Squibb Co. | 158.92B |
| Repligen Corp. | 10.13B |
| Johnson & Johnson | 644.86B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 75.43M |
| Revenue (Quarterly) | 261.28M |
| Total Expenses (Quarterly) | 185.85M |
| EPS Diluted (Quarterly) | 1.284 |
| Gross Profit Margin (Quarterly) | 73.53% |
| Profit Margin (Quarterly) | 28.87% |
| Earnings Yield | 7.78% |
| Operating Earnings Yield | 9.91% |
| Normalized Earnings Yield | 7.785 |